about
Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factorsCRISPR/Cas9 and cancer targets: future possibilities and present challengesRecent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingCancer Metabolism and Drug ResistanceExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesBiosafe nanoscale pharmaceutical adjuvant materialsPolymer-drug conjugates: origins, progress to date and future directionsThyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapyHigh expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicinAn ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegansAnticancer compound plumbagin and its molecular targets: a structural insight into the inhibitory mechanisms using computational approachesMutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsChemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.Research perspectives: gold nanoparticles in cancer theranosticsRecent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingHPMA copolymers: origins, early developments, present, and future.MUC1: a multifaceted oncoprotein with a key role in cancer progression.Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugsTumor metabolism, cancer cell transporters, and microenvironmental resistance.In silico screening for inhibitors of p-glycoprotein that target the nucleotide binding domains.Nanotechnology in dermatology.Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90β as a Novel Mechanism of Rifampin-induced MDR1 ExpressionUnique structure and regulation of the nematode detoxification gene regulator, SKN-1: implications to understanding and controlling drug resistanceChallenges and Potential for Ovarian Preservation with SERMs.Skin-safe photothermal therapy enabled by responsive release of acid-activated membrane-disruptive polymer from polydopamine nanoparticle upon very low laser irradiation.Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micellesMechanisms of chemoresistance to alkylating agents in malignant glioma.Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation siteAssessment of multidrug resistance on cell coculture patterns using scanning electrochemical microscopyFerrocenyl 2,5-Piperazinediones as Tubulin-Binding Organometallic ABCB1 and ABCG2 Inhibitors Active against MDR Cells.Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: basic science, research tools, and clinical applicationsTargeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cellsDaunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo.Microtubule stabilising agents for cancer chemotherapy.Light-Responsive Biodegradable Nanomedicine Overcomes Multidrug Resistance via NO-Enhanced Chemosensitization.Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment.Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy.
P2860
Q24303560-F210D522-50C7-41B2-B74E-0646D3E6F1E7Q26769907-54A699C5-E8EA-4423-BEC5-3ED315DC5958Q26778234-3A2F1BB7-3363-4DC0-AA4C-3D949A59236AQ26782042-CEA4A316-29D2-4DEF-900D-6530342AC344Q26828930-A677D3CB-A24F-4A61-AB37-E0A2B1A80171Q26829798-08493136-6C9F-49A2-81AF-50DACDA55DE5Q27002505-C3E9AAB5-B969-47E9-BE40-69260AF4F6BCQ28071977-13A4105A-F2FE-48C9-8146-638E7DAB57BAQ28468665-D73F8340-9673-43BF-B5B3-3248C55235CEQ28487176-68EB189D-A782-410D-BE6E-B66CBADBB567Q28540187-DE8E3130-2A71-413C-A71F-17B28FE57D22Q28541763-30B89C7E-6B12-447F-93F8-79E0D30D0EC8Q30403036-7A4511FE-D27D-492F-81D9-05E48BA1B0FFQ30444675-F11D36C7-E9F6-4A9D-8069-4C214C5B6F4FQ30456053-037E91BC-4F3B-43F3-B2CC-E4D0700527AFQ33719148-1D6B7CE1-8F9D-4027-845E-52479668EC64Q33880143-3BB409B6-5610-4D66-8B02-34D61A82ECEFQ33936160-7200A61B-3F74-458B-A01C-4C0C5AA77140Q34513382-F9122112-0CA2-4317-B3CE-97DF29509A6DQ34573936-C58CA1B1-B571-4E4A-AE8C-65E62A9CA216Q35120307-C425F4A9-4206-4773-BEB9-DF6CB91FC37CQ35164664-276ED83D-4D9D-4333-878D-C5382DAFEF99Q35860589-72F3FF83-73BB-44E8-8F6E-6A680C3617F9Q36099627-51A1000C-9093-43B5-A82A-3815B0A6F4EDQ36282795-FCFBB092-EAD5-45AA-A7F8-6A58BC0B4166Q36366662-7FC17620-9036-43BE-BCB8-1A028BA68E7BQ36501393-9F7BA214-B2B3-4E94-91D2-FCA11E16F330Q36726010-5361256F-61B9-4760-9F67-F03EB4161F41Q36837220-E008B30B-7118-4935-9243-0847393DC9A5Q36915386-E272BD39-BDE0-47F3-A847-7A3DF357E354Q36996281-13A9096E-5FA6-4E02-907B-3AA9A9D0A6CEQ37228573-3D5D05C6-505A-40EE-A013-DB5EB1438072Q37317194-7EE790A4-77F1-46C9-9B17-2E89AA443D3AQ37417566-2A474A38-D98B-4BC1-AEBD-82A799C570E3Q37481355-550BAC4D-5E31-490B-9C16-8E02F2450A74Q37584073-FEEF0C2E-4302-4F63-A6F8-14D0A5E02086Q37706632-E7EA278A-B29C-463C-A62D-31B0AFBD6FDFQ37714176-81C8BC86-7595-4F46-99D6-6E74A47C2628Q38165880-F54A7706-A8AE-4578-BFBC-996B07679156Q38204933-F9C12E20-5C1A-4E44-971E-984CB901133D
P2860
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Cancer multidrug resistance.
@en
type
label
Cancer multidrug resistance.
@en
prefLabel
Cancer multidrug resistance.
@en
P356
P1433
P1476
Cancer multidrug resistance.
@en
P2093
Persidis A
P2888
P356
10.1038/5289
P577
1999-01-01T00:00:00Z
P6179
1022509839